Elucid

Elucid is a medical technology company based in Boston, founded in 2013, that develops AI-powered cardiovascular imaging software. Its work centres on the non-invasive analysis of coronary CT angiography (CCTA) scans, with a focus on characterising arterial plaque. The company employs 51 people.

The firm's principal product is PlaqueIQ™, described as the first and only FDA-cleared, non-invasive plaque analysis software validated against ground-truth histology. The software quantifies and classifies plaque morphology from CCTA images, including lipid-rich necrotic core, calcified and non-calcified components, giving clinicians an objective measure of plaque composition without an invasive procedure.

Elucid operates in the medical imaging, cardiology and healthcare markets. The clinical problem it addresses is substantial: cardiovascular disease is the leading cause of death globally, and roughly half of Americans aged 45 to 84 are estimated to have atherosclerosis without knowing it. Regulatory clearance and histology validation are central to the company's position with hospital systems, imaging centres and cardiology practices.

The company was founded by Andrew J. Buckler and James Hamilton and describes its team as focused on improving the understanding and treatment of cardiovascular disease, with an emphasis on preventing heart attacks and strokes.